Infectious Serologies and Autoantibodies in Inflammatory Bowel Disease

The aim of this study was to reevaluate the role of infection in inflammatory bowel disease (IBD). Sera from 119 patients with IBD [80 with Crohn's disease (CD); 39 with ulcerative colitis] and 98 healthy controls were assessed using the Bio‐Rad BioPlex 2200 for the presence of Toxoplasma gondii, cytomegalovirus, Epstein–Barr virus, Treponema pallidum, and Saccharomyces cerevisiae. Hepatitis B virus, hepatitis C virus (HCV), and anti‐Helicobacter pylori antibodies were assessed by ELISA. In addition, sera were tested for a panel of antibodies associated with thrombophilia as well as various autoantibodies. Titers of antibodies toward HCV and T. gondii, and S. cerevisiae were higher in IBD patients than in controls, while the H. pylori autoantibodies were less prevalent among the patient population. Several thrombophilia‐associated antibodies were more common in CD patients, and a single patient had a thromboembolic event. Our results show an excess of anti‐HCV and anti‐T. gondii antibodies among patients with IBD compared to healthy controls. Whereas the former may be the result of immunosuppression from the inflammatory disease itself or from the medications used to treat it, the latter association suggests that T. gondii is involved in the etiopathogenesis of IBD, and especially CD, in humans, as has been shown in the murine model. However, our findings also reiterate the positive association between CD and anti‐S. cerevisiae antibodies as well as the negative association with H. pylori infections. These, in turn, lend indirect support to the “hygiene hypothesis” in IBD as well as the newly proposed role of commensal bacteria in the initiation of the disease process.

[1]  R. Pounder,et al.  PATHOGENESIS OF CROHN'S DISEASE: MULTIFOCAL GASTROINTESTINAL INFARCTION , 1989, The Lancet.

[2]  R. Aminov,et al.  Commensal gut bacteria: mechanisms of immune modulation. , 2005, Trends in immunology.

[3]  A. Püspök,et al.  Influence of Helicobacter pylori infection on the phenotype of Crohn's disease , 1999, American Journal of Gastroenterology.

[4]  H. Rautelin,et al.  Inverse correlation between Helicobacter pylori infection and inflammatory bowel disease. , 1996, Journal of clinical pathology.

[5]  J. N. Morris Controlled trial of soyabean oil in myocardial infarction. , 1968 .

[6]  A. Griffiths,et al.  Type I interferons for induction of remission in ulcerative colitis. , 2008, The Cochrane database of systematic reviews.

[7]  A. Rahbar,et al.  Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease , 2006, Journal of Autoimmunity.

[8]  Y. Shoenfeld,et al.  Epstein–Barr Virus and Cytomegalovirus in Autoimmune Diseases , 2007, Annals of the New York Academy of Sciences.

[9]  A. Antonelli,et al.  Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia. , 2008, Autoimmunity reviews.

[10]  M. Bardella,et al.  Possible Protective Effect of 5-Aminosalicylic Acid on Helicobacter pylori Infection in Patients With Inflammatory Bowel Disease , 2003, Journal of clinical gastroenterology.

[11]  J. Lennard-jones,et al.  MYCOBACTERIA AS A POSSIBLE CAUSE OF INFLAMMATORY BOWEL DISEASE , 1978, The Lancet.

[12]  P. Rutgeerts,et al.  Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum , 1991, The Lancet.

[13]  P. Mannucci,et al.  High Prevalence of Hyperhomocysteinemia in Patients with Inflammatory Bowel Disease: a Pathogenic Link with Thromboembolic Complications? , 1998, Thrombosis and Haemostasis.

[14]  E. El-Omar,et al.  Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. , 1994, Gut.

[15]  H. Tilg,et al.  A randomized placebo-controlled trial of pegylated interferon alpha in active ulcerative colitis , 2003 .

[16]  L. Piao,et al.  Toxoplasma gondii infection inhibits the development of lupus-like syndrome in autoimmune (New Zealand Black x New Zealand White) F1 mice. , 2004, International immunology.

[17]  C. Pearce,et al.  Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease , 2000, European journal of gastroenterology & hepatology.

[18]  Y. Haga [Mycobacteria in Crohn's disease]. , 1986, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

[19]  T. Karttunen,et al.  Seroprevalence of Helicobacter pylori Infection in Inflammatory Bowel Disease: Is Helicobacter pylori Infection a Protective Factor? , 2001, Scandinavian journal of gastroenterology.

[20]  S. Saibeni,et al.  Onset of inflammatory bowel diseases during combined alpha-interferon and ribavirin therapy for chronic hepatitis C: report of two cases. , 2005, European journal of gastroenterology & hepatology.

[21]  Y. Shoenfeld,et al.  Anti‐infectious Antibodies and Autoimmune‐associated Autoantibodies in Patients with Type I Diabetes Mellitus and their Close Family Members , 2009, Annals of the New York Academy of Sciences.

[22]  I. Mackay,et al.  The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases--2008. , 2008, The Israel Medical Association journal : IMAJ.

[23]  M. Boaz,et al.  Neuropsychiatric lupus and infectious triggers , 2008, Lupus.

[24]  Y. Shoenfeld,et al.  Systemic Thromboembolism in Inflammatory Bowel Disease: Mechanisms and Clinical Applications , 2005, Annals of the New York Academy of Sciences.

[25]  Yu Chen,et al.  Inverse associations of Helicobacter pylori with asthma and allergy. , 2007, Archives of internal medicine.

[26]  E. Kouroumalis,et al.  Anti-cardiolipin and Anti-β2-glycoprotein I Antibodies in Patients with Inflammatory Bowel Disease , 1998, Digestive Diseases and Sciences.

[27]  F. Shanahan,et al.  Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V Leiden. , 1997, QJM : monthly journal of the Association of Physicians.

[28]  C. Bernstein,et al.  Population‐based case‐control study of measles, mumps, and rubella and inflammatory bowel disease , 2007, Inflammatory bowel diseases.

[29]  A. Axon,et al.  Prevalence of Helicobacter pylori infection and related upper gastrointestinal lesions in patients with inflammatory bowel diseases. A cross-sectional study with matching. , 1997, Scandinavian journal of gastroenterology.

[30]  R. D'Incà,et al.  Hepatitis B and C Virus Infection in Crohn's Disease , 2001, Inflammatory bowel diseases.

[31]  A. Neugut,et al.  Inflammatory Bowel Disease in Patients with Celiac Disease , 2005, Inflammatory bowel diseases.

[32]  J. Freyssinet,et al.  Prevalence and significance of anticardiolipin antibodies in Crohn's disease , 1994, Digestive Diseases and Sciences.

[33]  H. Tilg,et al.  A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. , 2003, Gut.

[34]  U. Göbel,et al.  Exacerbation of murine ileitis by Toll-like receptor 4 mediated sensing of lipopolysaccharide from commensal Escherichia coli , 2007, Gut.

[35]  E. Seidman,et al.  Investigating the Hygiene Hypothesis as a Risk Factor in Pediatric Onset Crohn's Disease: A Case-Control Study , 2006, The American Journal of Gastroenterology.

[36]  R. Sidhu,et al.  Is there an association between coeliac disease and inflammatory bowel diseases? A study of relative prevalence in comparison with population controls , 2007, Scandinavian journal of gastroenterology.

[37]  M. Behr,et al.  Mycobacteria in Crohn's disease: a persistent hypothesis. , 2006, Inflammatory bowel diseases.